FGF23 Inhibitors
1 drugsAbout FGF23
FGF23 is a circulating hormone regulating phosphate and vitamin D metabolism. Dysregulation of FGF23 can disrupt phosphate homeostasis.
Currently, there is no genetic evidence linking FGF23 directly to specific diseases. However, its role in phosphate metabolism makes it a therapeutic target.
FGF23 is targeted by one approved drug, CRYSVITA (burosumab), a biologic. KYOWA KIRIN is the only company with an approved FGF23-targeting therapy.
Top FGF23 Drugs
KYOWA KIRIN is the only company with an approved drug targeting FGF23.
High market concentration suggests high entry barriers or limited interest.
FGF23 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets FGF23, using biologic (other) modality.
The absence of small molecule drugs indicates a potential whitespace opportunity.
FGF23 Clinical Trials 13 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on FGF23. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 4 | 4 | 0 | 0 | 100% |
| Phase 3 | 6 | 6 | 0 | 0 | 100% |
| Phase 4 | 2 | 2 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
FGF23 Drug Approval Timeline (2018 - 2018)
The first and only drug, CRYSVITA, was approved in 2018.
Recent entry suggests growth potential, but also possible market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 7 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on FGF23. A trial counts if an approved drug acting on FGF23 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.